Interferon gamma-1b in the treatment of idiopathic pulmonary fibrosis

Annals of Pharmacotherapy

Volumn 39, Issue 10, 2005, Pages 1678-1686

  Pacanowski, Michael A ^a   Amsden, Guy W ^a,b  

^a Bassett Healthcare ^*  (United States)

^b BASSETT RESEARCH INSTITUTE   (United States)

Author keywords

Cryptogenic fibrosing alveolitis; Idiopathic pulmonary fibrosis; Interferon

Indexed keywords

AMINOTRANSFERASE; AZATHIOPRINE; COLCHICINE; CORTICOSTEROID; GAMMA1B INTERFERON; PREDNISONE;

AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; BONE PAIN; BRONCHIOLITIS; CENTRAL NERVOUS SYSTEM DISEASE; CHILL; CLINICAL TRIAL; COUGHING; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FATIGUE; FEVER; FLU LIKE SYNDROME; GAIT DISORDER; HEADACHE; HUMAN; IDIOPATHIC DISEASE; INFLAMMATION; LUNG FIBROSIS; LUNG FUNCTION; LYMPHOCYTOPENIA; MIGRAINE; MORTALITY; MYALGIA; NAUSEA; NEUTROPENIA; NOSE CONGESTION; PAIN; PRIORITY JOURNAL; RESPIRATORY FAILURE; REVIEW; RIGOR; SIDE EFFECT; SURVIVAL; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

CLINICAL TRIALS; HUMANS; INTERFERON-GAMMA, RECOMBINANT; MEDLINE; PULMONARY FIBROSIS; TREATMENT OUTCOME;

EID: 25844483272     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E672     Document Type: Review

References (59)

1. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med 2000;161:646-64.
2. Panos RJ, Mortenson RL, Niccoli SA, King TE. Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. Am J Med 1990;88:396-404.
3. Bjoraker JA, Ryu JH, Edwin MK, Myers JL, Tazelaar HD, Schroeder DR, et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998;157:199-203.
4. Schwartz DA, Helmers RA, Galvin JR, Van Fossen DS, Frees KL, Dayton CS, et al. Determinants of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1994;149:450-4.
5. King TE, Tooze JA, Schwarz MJ, Brown KR, Cherniack RM. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med 2001;164:1171-81.
6. Hubbard R, Johnston I, Britton J. Survival in patients with cryptogenic fibrosing alveolitis: a population based cohort study. Chest 1998;113: 396-400.
7. Selman M, Thannickal VJ, Pardo A, Zisman DA, Martinez FJ, Lynch JP. Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches. Drugs 2004;64:405-30.
8. Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001;134:136-51.
9. Prescribing information. Actimmune (interferon gamma-1b). Brisbane, CA: InterMune, March 2004.
10. Gay SE, Kazerooni EA, Toews GB, Lynch JP, Gross BH, Cascade PN, et al. Idiopathic pulmonary fibrosis: predicting response to therapy and survival. Am J Respir Crit Care Med 1998;157:1063-72.
11. King TE, Schwarz MI, Brown K, Tooze JA, Colby TV, Waldron JA, et al. Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality. Am J Respir Crit Care Med 2001;164:1025-32.
12. Latsi PU, du Bois RM, Nicholson AG, Colby TV, Bisirtzoglou D, Nikolakopoulou A, et al. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 2003;168:531-7.
13. Hanson D, Winterbauer RH, Kirtland SH, Wu R. Changes in pulmonary function test results after one year of therapy as predictors of survival in patients with idiopathic pulmonary fibrosis. Chest 1995;108:305-10.
14. Gross TJ, Hunninghake GW. Idiopathic pulmonary fibrosis. N Engl J Med 2001;345:517-25.
15. Flaherty KR, Toews GB, Lynch JP, Kazerooni EA, Gross BH, Strawderman RL, et al. Steroids in idiopathic pulmonary fibrosis: a prospective assessment of adverse reactions, response to therapy, and survival. Am J Med 2001;110:278-82.
16. Timmer SJ, Karamzadeh AM, Yung GL, Kriett J, Jamieson SW, Smith CM. Predicting survival of lung transplantation candidates with idiopathic interstitial pneumonia. Chest 2002;122:779-84.
17. Erbes R, Schaberg T, Loddenkemper R. Lung function tests in patients with idiopathic pulmonary fibrosis: are they helpful for predicting outcome? Chest 1997;111:51-7.
18. Flaherty KR, Thwaite EL, Kazerooni EA, Gross BH, Toews GB, Colby TV, et al. Radiological versus histological diagnosis in UIP and NSIP: survival implications. Thorax 2003;58:143-8.
19. Collard HR, King TE, Bartelson BB, Vourlekis JS, Schwanz MI, Brown KK. Changes in clinical and physiological variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003;168: 538-42.
20. Flaherty KR, Mumford JA, Murray S, Kazerooni EA, Gross BH, Colby TV, et al. Prognostic implications of physiologic and radiologic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003; 168:543-8.
21. Nicholson A, Colby TV, du Bois RM, Hansell DM, Wells AU. The prognostic significance of the histologic pattern of interstitial prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 2000;162:2213-7.
22. Nicholson AG, Fulford LG, Colby TV, du Bois RM, Hansell DM, Wells AU. The relationship between individual histologic features and disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2002;166:173-7.
23. Daniil ZD, Gilchrist FC, Nicholson AG, Hansell DM, Harris J, Colby TV, et al. A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 1999;160:899-905.
24. Flaherty KR, Toews GB, Travis WS, Colby TV, Kazerooni EA, Gross BH, et al. Clinical significance of idiopathic interstitial pneumonias. Eur Respir J 2002;19:275-83.
25. King TE, Safrin S, Starko KM, Brown KK, Noble PW, Raghu G, et al. Analyses of efficacy end points in a controlled trial of interferon-γ1b for idiopathic pulmonary fibrosis. Chest 2005;127:171-7.
26. Katzenstein AA, Myers JL. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med 1998;157: 1301-15.
27. Wallace WAH, Howie SEM. Immunoreactive interleukin 4 and interferon-γ expression by type II alveolar epithelial cells in interstitial lung disease. J Pathol 1999;187:475-80.
28. Douglas WW, Ryu JH, Schroeder DR. Idiopathic pulmonary fibrosis: impact of oxygen and colchicine, prednisone, or no therapy on survival. Am J Respir Crit Care Med 2000;161:1172-8.
29. Raghu G, Depaso WJ, Cain K, Hammar SP, Wetzel CE, Dreis DF, et al. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled trial. Am Rev Respir Dis 1991;144:291-6.
30. Zisman DA, Lynch JP, Toews GB, Kazerooni EA, Flint A, Martinez FJ. Cyclophosphamide in the treatment of idiopathic pulmonary fibrosis: a prospective study in patients who failed to respond to corticosteroids. Chest 2000;117:1619-26.
31. Johnson MA, Kwan S, Snell NJC, Nunn AJ, Darbyshire JH, Turner-Warwick M. Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis. Thorax 1989;44:280-8.
32. Selman M, Carrillo G, Salas J, Padilla RP, Perez-Chavira R, Sansores R, et al. Colchicine, D-penicillamine, and prednisone in the treatment of idiopathic pulmonary fibrosis: a controlled trial. Chest 1998;114:507-12.
33. Douglas WW, Ryu JH, Swense SJ, Offord KP, Schroder DR, Caron GM, et al. Am J Respir Crit Care Med 1998;158:220-5.
34. Ziesche R, Hofbauer E, Wittmann K, Petkov V, Block LH. A preliminary study of long-term treatment with interferon gamma-1b and low dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med 1999;341:1264-9.
35. Ziesche R, Bradford WZ, Crager M, Block L-H. Long-term survival in idiopathic pulmonary fibrosis patients treated with interferon gamma-1b. Chest 2002;122(suppl):75S-6S.
36. Raghu G, Brown KK, Bradford WZ, Starko K, Noble PW, Schwartz DA, et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004;350:125-33.
37. Raghu G, Spada C, Otaki Y, Hayes J. Interferon gamma in the treatment of advanced idiopathic pulmonary fibrosis and fibrotic nonspecific interstitial pneumonia: prospective, preliminary clinical observations in one center (abstract). Chest 2001;120(suppl):185S.
38. Antoniou KM, Polychronopoulos V, Dimadi M, Rapti A, Lambrakis C, Latsi P, et al. Comparison of interferon gamma-1b (IFN γ-1b) and colchicine in the treatment of idiopathic pulmonary fibrosis: interim results of a prospective, multicenter randomized study (poster). Presented at: 99th International Conference of the American Thoracic Society, Seattle, May 16-21, 2003.
39. Bell AM, Nathan SD, Shorr AF, Barnett SD, Helman DL. The effect of interferon alone vs interferon plus corticosteroids in patients with idiopathic pulmonary fibrosis (abstract). Chest 2003;124:1175.
40. Stricter RM, Starko KM, Enelow RI, Noth I, Valentine VG, Idiopathic Pulmonary Fibrosis Biomarkers Study Group. Effects of interferon-γ 1b on biomarker expression in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2004;170:133-40.
41. Kalra S, Utz JP, Ryu JH. Interferon gamma-1b therapy for advanced idiopathic pulmonary fibrosis. Mayo Clin Proc 2003;78:1082-7.
42. Nathan SD, Barnett SD, Moran B, Kelman DL, Nicholson K, Ahmad S, et al. Interferon gamma-1b as therapy for idiopathic pulmonary fibrosis: an intrapatient analysis. Respiration 2004;71:77-82.
43. Ziesche R, Kink E, Herold C, Podolsky A, Block LH. Therapy of chronic interstitial lung disease with a combination of interferon-γ and low dose prednisolone (abstract). Chest 1996;110(suppl):25S.
44. Prasse A, Muller KM, Kurz C, Hamm H, Virchow JC. Does interferon-γ improve pulmonary function in idiopathic pulmonary fibrosis? Eur Respir J 2003;22:906-11.
45. Bienkowski RS, Gotkin MG. Control of collagen deposition in mammalian lung. Proc Soc Exp Biol Med 1995;209:118-40.
46. Jiang D, Liang J, Hodge J, Lu B, Zhu Z, Yu S, et al. Regulation of pulmonary fibrosis by chemokine receptor CXCR3. J Clin Invest 2004;114: 291-9.
47. Elias JA, Freundlich B, Kern JA, Rosenbloom J. Cytokine networks in the regulation of inflammation and fibrosis in the lung. Chest 1990;97; 1439-45.
48. Narayanan AS, Whithey J, Souza A, Raghu G. Effect of γ-interferon on collagen synthesis by normal and fibrotic human lung fibroblasts. Chest 1992;101:1326-31.
49. Clark JG, Dedon TF, Wayner EA, Carter WG. Effects of interferon-γ on expression of cell surface receptors for collagen and deposition of newly synthesized collagen by cultured human lung fibroblasts. J Clin Invest 1989;83:1505-11.
50. Okada T, Sugie I, Aisaka K. Effects of gamma-interferon on collagen and histamine content in bleomycin-induced lung fibrosis in rats. Lymphokine Cytokine Res 1993;12:87-91.
51. Sempowski GD, Derdak S, Phipps RP. Interleukin-4 and interferon-γ discordantly regulate collagen biosynthesis by functionally distinct lung fibroblast subsets. J Cell Physiol 1996;167:290-6.
52. Gurujeyalakshmi G, Giri SN. Molecular mechanisms of antifibrotic effect of interferon gamma in bleomycin-mouse model of lung fibrosis: downregulation of TFG-beta and procollagen I and III gene expression. Exp Lung Res 1995;21:791-808.
53. Venkatesan N, Roughley PJ, Ludwig MS. Proteoglycan expression in lung fibroblasts: role of transforming growth factor beta-1 and interferon-gamma. Am J Physiol Lung Cell Mol Physiol 2002;283:L806-14.
54. Data on file. InterMune, Brisbane, CA, 2004.
55. Prior C, Haslam PL. In vivo levels and in vitro production of interferon-gamma in fibrosing interstitial lung diseases. Clin Exp Immunol 1992; 88:280-7.
56. Wen F, Liu X, Kobayashi T, Abe S, Fang Q, Kohyama T, et al. Interferon-γ inhibits transforming growth factor-β production in human airway epithelial cells by targeting smads. Am J Respir Cell Mol Biol 2004; 30:816-22.
57. Honore I, Nunes H, Groussard O, Kambouchner M, Chambellan A, Aubier M, et al. Acute respiratory failure after interferon gamma therapy of end-stage pulmonary fibrosis. Am J Respir Crit Care Med 2003;167: 953-7.
58. Crestani B, Valeyre D. Acute respiratory failure after interferon-γ therapy in IPF. Am J Respir Crit Care Med 2004;169:543-4.
59. 2004 Drug topics red book. Montvale, NJ: Thompson PDR, 2004.